{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '15. Current drug or alcohol abuse, or history of either within the previous 2 years, in the opinion of the', 'Investigator or as reported by the subject.', '16. Biopsy-proven or clinically suspected inflammatory bowel disease (e.g., diarrhea with or without blood', 'or rectal bleeding associated with abdominal pain or cramping/colic, urgency, tenesmus, or', 'incontinence for more than 4 weeks without a confirmed alternative diagnosis OR endoscopic or', 'radiologic evidence of enteritis/colitis without a confirmed alternative diagnosis).', '17. Known hypersensitivity to any of the components of teprotumumab or prior hypersensitivity reactions', 'to mAbs.', '18. Any other condition that, in the opinion of the Investigator, would preclude inclusion in the study.', '19. Previous enrollment in this study or participation in a prior teprotumumab clinical trial.', '20. HIV, hepatitis C or hepatitis B infections.', 'Dose Regimen/Route of Administration:', 'All study drug dosing will be performed at the clinic under the supervision of clinic staff. On Day 1 of the', 'double-masked Treatment Period, subjects will be randomized in a 1:1 ratio (stratified by tobacco use status) to', 'receive infusions of either:', '1. Teprotumumab 20 mg/kg (10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions),', 'or', '2. Placebo (q3W for all 8 infusions).', 'The infusion rate may be reduced and the dose may be interrupted or held based on tolerability (see', 'Section 9.4.6.3.2 for details). The first and second infusions will be administered over approximately 90 minutes', '(but not less than 80 minutes). Subsequent infusions will be administered over approximately 60 minutes (but', 'not less than 50 minutes), providing there are no significant infusion-associated events.', 'Dosage Form and Strength Formulation:', 'Teprotumumab 500 mg will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of', 'teprotumumab will be reconstituted with 10 mL of water for injection. The resulting solution will have an', 'approximate concentration of 50 mg/mL teprotumumab. Reconstituted teprotumumab solution will be further', 'diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration.', 'Doses up to 1800 mg will be administered in a total infusion volume of 100 mL, and those above 1800 mg will', 'be administered in a total infusion volume of 250 mL. To maintain a constant volume in the infusion bags, a', 'volume equal to the volume of teprotumumab to be placed into the infusion bag will be first removed from the', 'infusion bag using a sterile syringe and needle. The appropriate volume of reconstituted drug product solution', \"based on the subject's dose and body weight will be withdrawn and the teprotumumab reconstituted drug\", 'product solution will be diluted with normal saline (0.9% NaCl) in the infusion bag.', 'Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL', 'infusion bags, as appropriate, per weight-based dosing volumes.', 'Duration of Treatment and Follow-Up:', 'The planned duration of the double-masked Treatment Period is 24 weeks (6 months). Subjects who are', 'considered proptosis non-responders at Week 24 or subjects who were responders at Week 24 but who meet', 'criteria for re-treatment due to relapse during the Follow-Up Period may enroll in the open-label extension', 'study, HZNP-TEP-302 (see Section 9.3.4).', 'At Week 24, proptosis responders, as well as non-responders who choose not to enroll in the open-label', 'extension study, will enter a 48-week Follow-Up Period.', 'Subjects who complete the Week 72 Visit will be contacted 6 and 12 months later via phone or email by', 'research staff to enquire if any treatment for TED has been received since last study contact.', 'Criteria for Evaluation:', 'The most severely affected eye will be defined as the \"study eye\" at the Baseline (Day 1) Visit. If there is a', 'discrepancy between CAS and proptosis in determining the study eye, this will be adjudicated always to the eye', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 26 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'with the most significant proptosis. If both eyes are affected equally, the Investigator will choose the \"study', 'eye\". Both eyes will be assessed for efficacy but the study eye will be used to assess the primary outcome', 'measure.', 'Efficacy will be assessed by proptosis (measured as exophthalmos evaluation of the Clinical Measures of', 'Severity using a Hertel instrument provided by the Sponsor for consistency in measurement), CAS (7-item', 'scale), diplopia (measured as part of the Clinical Measures of Severity), and Clinical Measures of Severity', '(including motility restriction assessments).', 'Quality of life will be assessed using the GO-QoL questionnaire.', 'Blood samples for teprotumumab PK assessment will be collected prior to, and at the end of, the infusion on', 'Day 1 and Weeks 3 and 9 during the Treatment Period; in addition, single samples will be collected at Weeks 1,', '4, and 24. PK/PD relationships will be explored.', 'Serum samples may be analyzed for biomarkers (IL-4, IL-6, IL-10, IL-12, IL-13, IL-17, IL-23, IL-1B, sIL-1RA,', 'INFy, TGF\u00df, TNFa, and micRNA) and possibly functional thyroid stimulating hormone receptor stimulating,', 'blocking, and binding antibody (TSH-R-Ab) during the Treatment Period. Based on the results of the above', 'assays, other similar serum biomarkers may be assayed to further explore drug and disease mechanisms.', 'Safety will be assessed via AE and concomitant medication use monitoring, immunogenicity testing, physical', 'and ophthalmic examinations, vital signs, clinical safety laboratory evaluations (complete blood count,', 'chemistry (including thyroid panel and HbA1c), and urinalysis), pregnancy testing (if applicable), and', 'electrocardiograms (ECG). The study will also be monitored by a Data Safety Monitoring Board (DSMB).', 'Statistical Analyses:', 'Primary Efficacy Endpoint', 'The primary outcome measure is the effect of teprotumumab versus placebo on the proptosis responder rate', '(percentage of subjects with a > 2 mm reduction from Baseline in proptosis in the study eye, without', 'deterioration 2 mm increase] of proptosis in the fellow eye) at Week 24.', 'Secondary Efficacy Endpoints (analyzed hierarchically)', '1. The effect of teprotumumab versus placebo on the overall responder rate (percentage of subjects with', '> 2-point reduction in CAS AND > 2 mm reduction in proptosis from Baseline, provided there is no', 'corresponding deterioration [ 2-point/mm increase] in CAS or proptosis in the fellow eye) at', 'Week 24.', '2.', 'The effect of teprotumumab versus placebo on the percentage of subjects with a CAS value of 0 or 1 at', 'Week 24 in the study eye.', '3. The effect of teprotumumab versus placebo on the mean change from Baseline to Week 24 in proptosis', 'measurement in the study eye.', '4.', 'The effect of teprotumumab versus placebo on the diplopia responder rate (percentage of subjects with', 'baseline diplopia 0 in study eye who have a reduction of 1 grade with no corresponding', 'deterioration 1 grade worsening] in the fellow eye) at Week 24.', '5.', 'The effect of teprotumumab versus placebo on the mean change from Baseline to Week 24 in the', 'GO-QoL questionnaire overall score.', 'Exploratory Efficacy Endpoints', '1. The effect of teprotumumab versus placebo on the Clinical Measures of Severity individual response', 'status frequencies and percentage of responders for each component of clinical severity from Baseline', 'to Week 24.', '2. The effect of teprotumumab versus placebo on the mean change from Baseline to Week 24 in the CAS.', '3. The effect of teprotumumab versus placebo on the overall responder rate at Week 24 stratified by the', 'level of response (high responders, responders, low responders, and non-responders).', '4. To evaluate the PK parameters of teprotumumab to estimate exposure and understand the PK-PD', 'relationships.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 27 of 117']\n\n###\n\n", "completion": "END"}